Immunohistochemical Expression and Histopathological Role of CD47 in Colorectal Cancer in Iraqi Patients

Fatima O. Abdalkareem 1, Ban J. Mohamad 1

1 Department of Biology, College of Science, University of Baghdad. Baghdad, Iraq.

Abstract

Background: Bowel cancer is the most prevalent digestive system cancer and is the 4th largest cause of cancer-related death worldwide. In Iraq, colon and rectal cancer (CRC) is the 6th most common malignancy in males and the 5th in females. This cancer is sluggish in growth, which gives a window of opportunity to screen for both precursor lesions and early cancer. The Cluster of Differentiation 47 (CD47) protein is a type of transmembrane glycoproteins found on nearly all human cells, including non-hematopoietic and hematopoietic cells. CD47 promotes CRC growth by triggering angiogenesis and apoptosis of tumor cell.

Objectives: To evaluate the immunohistochemical expression of (CD47) in various colorectal samples from Iraqi patients with CRC by immunohistochemistry (IHC) assay.

Specimens and methods: A total of 45 paraffin-embedded CRC tissue specimens and clinical data were obtained from the Medical City Teaching Hospital in Baghdad and a number of private laboratories in Baghdad, Iraq. In addition, 30 control colon and rectum tissues with no significant pathology were collected from the Forensic Medicine Department for comparison purposes after taking the official approvals.

Results: The results revealed a high expression of CD47 in CRC cases, but with no significant correlation with clinicopathological features. Also, the result of figures in this study revealed negative membranous expression of CD47 (score 0), strong membranous expression of CD47 (score 8), moderately membranous expression of CD47 (score 7), and weak membranous expression of CD47 (score 4).

Conclusion: Patients with CRC had high CD47 expression, allowing tumor cells to modulate CD47SIRP inhibitory signaling and prevent immune cell attack.

Keywords: Colorectal cancer; Cluster of Differentiation 47; Immunohistochemistry; Integrin-associated protein.

Introduction

Colon and rectal cancer (CRC), also known as bowel cancer, is the 4th most prevalent malignant disease worldwide, characterized by irregular growth of the colon epithelium which occupies the entire wall thickness of the colon, with metastasis to the surrounding lymph nodes and neighboring tissues, and finally distant metastatic spread (1). Most CRCs are slow-growing lesions that develop from polyps that are adenomatous or sessile serrated lesions (2). The probability of developing CRC is influenced by genetic and/or environmental factors (3).

CRC begins with vague signs and symptoms such as altered bowel habits, including constipation or diarrhea, changes in stool consistency, bleeding from the rectum, persistent gastrointestinal discomfort, e.g., cramps, pain or gases, tenesmus, fatigue, and unexplained weight loss. Screening for CRC can be done by measuring serum levels of various tumor markers, such as CA19-9, CEA, CCSA-3, and CCSA-4 (4).

In accordance with the American Cancer Society, approximately 1 in 21 males and 1 in 23 females in the United States will develop CRC over their lifetime (5).

CRC can be classified as proximal or right side if it develops from proximal portions to the splenic flexure (cecum, transverse colon and ascending colon), distal or left side if it originates distally to the descending colon or sigmoid, and rectal if it develops within 15 cm of the anal sphincter. (6).

CRC become more prevalent with increasing age, especially after the age of 55 years, with roughly 60% of the cases affecting those 70 years or older. Iraq has a low incidence of CRC, although it has been steadily increasing over time (7). Prediction models based on tumor markers, as well as clinicopathological and demographic factors, have recently been broadly developed for the prognosis of CRC (8).

Cluster of differentiation 47 (CD47) (also referred as OA3 and IAP) a transmembrane glycoprotein that is present on nearly all cells in the human body. CD47 was found independently in numerous cell types, resulting in a wide range of nomenclature. Because it was found to be associated with integrins, such as v3, on various types of cells, it was first referred as Integrin-Associated Protein (IAP). Furthermore,
being highly expressed on ovarian malignant cells, this antigen was also identified as OA3 (9). CD47 is the signaling receptor with high affinity for the secretory protein thrombospondin-1 (THBS1) and a counter-receptor for the signal regulatory protein alpha (SIRPα) (10). The binding of SIRPα to CD47 triggers SIRPα phosphorylation of ITIMs (immunoreceptor tyrosine-based inhibitory motifs) resulting in deactivation of myosin IIa, which is a critical step to block phagocytosis (11).

Specimens and Methods: From October 2022 to January 2023, 75 cases of colonic biopsies (excisional biopsy and total colectomy) were collected. The tissue samples were collected in the form of formalin-fixed paraffin-embedded (FFPE) blocks of tissue from the archive files of the Pathology Department/ Teaching Laboratories/ Baghdad Medical City Teaching Hospital and a number of private laboratories in Baghdad, Iraq. These samples belong to the years 2019, 2020, 2021, 2022, and 2023. The samples were further classified into 45 cases of malignant tumors from CRC cases and 30 colon biopsies from cadavers in the Forensic Medicine Department (not CRC cases) for comparison purposes after taking the official approvals. They were preserved in 10% formalin and grade were collected from the patients’ records. All the preparations for slide sectioning, Hematoxylin/Eosin staining, and IHC staining were performed at a private laboratory.

Immunohistochemistry staining: The specific antibody/antigen binding in tissue is the basic concept of this method. A variety of spotting techniques are then used to visualize the bound antigen-antibody complex. IHC detects the antigens of interest using a variety of enzymatic markers, including alkaline phosphatase and peroxidase (12). The IHC staining process was followed exactly as specified by the kit manufacturers’ protocols (Abcam, anti-CD47 antibody, EPR21794, ab218810 and PolyExcel, HRP/DAB Detection System). The general protocol was adopted in accordance with Magaki et al., 2019 (13). First, the tissue sections were de-waxed by heating the slides in an oven at 60-65°C for 30 minutes, followed by rapid rinsing in xylene and re-heating in the oven for 5 minutes. The sections were hydrated again via immersing them in concentrations of alcohol and cleared in xylene for two times at two minutes each. In the end, by using the DPX mounting medium, the slides were mounted and cover slipped.

Scoring system of immunohistochemistry: CD47 scoring system was applied according to Allred score (14). Allred score was calculated using the formula clarified in Table 1. The findings were evaluated and analyzed by a pathologist.

Statistical analysis

For data analysis, the SPSS-28 (Statistical Packages for Social Sciences - Version 28) was used. The data were presented in simple frequencies, percentages, means, standard deviations, and ranges. To test for associations between variables, the Chi-square test was performed (15), and a P value of <0.05 was considered significant.

Results

Immunohistochemical expression of CD47 in CRC: CD47 expression is observed in tumor cells as brown membranous staining (Figures: 1, 2, 3, and 4).

Figure 1: Strong membranous expression of CD47 in CRC (score 8) (4X)
Immunohistochemical Expression and Histopathological Role of CD47 in Colorectal Cancer in Iraqi Patients

Fatima O. Abdalkareem & Ban J. Mohamad

CD47 expression was positive in 91.1% of malignant cases, while it was negative in 100% of normal colorectal tissues, with a significant association, (Table 2).

Table 2: Expression of CD47 malignant colon tissue from CRC patients and controls

<table>
<thead>
<tr>
<th>Expression</th>
<th>CD47</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Malignant (%)</td>
<td>Control (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>41</td>
<td>91.1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>4</td>
<td>8.9</td>
<td>45</td>
<td>100</td>
</tr>
<tr>
<td>P value</td>
<td>(&lt;0.001) *</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Significant association between CD47 expression in CRC cases and controls using Chi-square test.

Association of CD47 with demographic and clinicopathological features: The results showed no significant associations between CD47 expression and age, gender, tumor site and diameter, tumor stage and grade, histological type, and lymph node metastasis (Table 3).

Table 3: Associations of CD47 with demographic and clinical variables in Iraqi CRC patients

<table>
<thead>
<tr>
<th>Clinicopathological features</th>
<th>CD47</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt;40</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>40-49</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>50-59</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>&gt;60</td>
<td>18</td>
<td>1</td>
</tr>
<tr>
<td>Gender Male</td>
<td>19</td>
<td>2</td>
</tr>
<tr>
<td>Female</td>
<td>22</td>
<td>2</td>
</tr>
<tr>
<td>Tumor Size &lt;5 cm</td>
<td>29</td>
<td>1</td>
</tr>
<tr>
<td>&gt;5 cm</td>
<td>12</td>
<td>3</td>
</tr>
<tr>
<td>Tumor Site Left</td>
<td>26</td>
<td>4</td>
</tr>
<tr>
<td>Right</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>13</td>
<td>3</td>
</tr>
<tr>
<td>IIIC</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>IIIA</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>IIIB</td>
<td>18</td>
<td>1</td>
</tr>
<tr>
<td>IIIIC</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Grade I</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>II</td>
<td>38</td>
<td>4</td>
</tr>
<tr>
<td>II</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Histological Type Adenocarcinoma</td>
<td>35</td>
<td>4</td>
</tr>
<tr>
<td>Mucinous</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Signet ring cell</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Lymph Node Metastasis Positive</td>
<td>19</td>
<td>0</td>
</tr>
<tr>
<td>Negative</td>
<td>22</td>
<td>4</td>
</tr>
</tbody>
</table>

No significant associations were found using the Chi-square test.

Discussion

In the recent years, extensive research has been carried out in an effort to predict illness progression and discover novel treatments for CRC. Immunotherapy has been a significant advance in cancer treatment. This immunotherapy works through blocking checkpoints, one of which is CD47 (16). CD47, an important molecule for the macrophage checkpoint, was discovered to be excessively expressed in the hematological and solid cancers with poor prognosis. CD47 tumor expression is associated with immune evasion via malignant cells through the CD47-SIRP alpha pathway (17). CD47 was first identified as a tumor antigen on human ovarian cancer in the 1980s, and its overexpression is associated with a poor prognosis in ovarian cancer (18).

Most normal cells have the CD47 integrin, which binds to the extracellular domain of SIRP on macrophages and inhibits their phagocytic activity. When mature blood cells, such as RBCs lose their CD47 molecules, they become the target for macrophage-mediated removal from the circulation (19). Cancer cells overexpress CD47 in order to...
avoid the innate immune response of M1 macrophages by attaching to their SIRP receptor. The host's adaptive and innate immune systems play essential roles in eliminating malignant cells and preventing progression of tumors, while cancer cells display immunological escape by expressing immune checkpoint proteins such as CD47 (20). When activated by CD47 binding, the regions of immunoreceptor tyrosine-based inhibitory motif (ITIM) turn into phosphorylated, resulting in activation and recruitment of the protein tyrosine phosphatases, which results in the de-phosphorylation of next molecules, like myosin IIA, and the suppression of phagocytosis activity (21). Many studies reported that expression of CD47 is a prognostic marker in many different types of malignancy (22).

In the current study, 45 cases of CRC were immunohistochemically examined for CD47, and the association of their CD47 expression with demographic and clinicopathological characteristics was investigated. The result demonstrated that CD47 was positively expressed in (91.1%) of all malignant cases. This result is in correspondence to those reported by Sugimura-Nagata et al who found a higher expression of CD47 in malignant than in normal cells. This suggests that the limitedly-expressed CD47-dependent activation of the CD47–SIRPA signaling in the CRC microenvironment has a significant impact on the clinical outcome of CRC, as similarly observed for other malignancies (17).

Another aspect of the current study is the association between CD47 expression and different demographic and clinicopathological features, especially age. The lack of association between the expression of CD47 and age groups is in agreement with the results of Fujiwara-Tani et al (23) who reported no such association between the expression of CD47 and age groups in CRC cases. A study on stomach cancer also found no such association (24).

In the current study, there was no association between tumor size and size of CRC with CD47 expression. These findings correspond with those reported by Hu et al (25). A study on gastric carcinoma (26) reported no association between expression of CD47 and tumor diameter and location. Moreover, there was no association between CD47 expression in CRC cases and gender in the current study, and in that conducted by Ji et al on CRC cases (27) and that conducted by Peng et al on lung squamous cell cancer (28).

The current study found no association between CD47 expression and the histological type of the malignant tumor. Similarly, Bang found no association between CD47 expression and histological type of non-melanoma skin cancers (29), while Sugimura-Nagata et al (17) reported that CD47 positivity was associated with histological differentiation in CRC. The current investigation found no association between CD47 and the stage or grade of CRC, whereas Yuan et al in their breast cancer study, found a statistically significant association between CD47 expression levels and the stage and grade of breast cancer (30).

Immune avoidance is critical for progressing to the developed stage of colorectal adenoma (CRA), and some researchers have found that a higher concentration of tumor-associated macrophage (TAM) associate with more developed CRC stages. This might indicate that, through the “don't eat me signal”, the CD47 expression, which inhibits phagocytic activity, rises in more developed stage as well (31). The current study found no association between CD47 expression and lymph node involvement. In CRC patients, CD47 was found to be strongly associated with recurrence, American Joint Committee on Cancer (AJCC) stage, and metastasis. A study on CD47 expression in triple negative breast cancer found no significant association with lymph node metastasis (32). These findings strongly suggest that CD47 expression may play an important role in controlling human CRA progression. Our findings show that CD47 overexpression enhances CRC metastasis and cell proliferation.

The differences between our results and those of other studies may due to differences in histological specimens, race, genetic factors, methodology and kits used. This is the first study in Iraq on CD47 in CRC patients.

Conclusions
The study suggests that increased CD47 expression in CRC patients, allows tumor cells to control CD47/SIRP inhibitory signals and prevent immune cell attack. There was no association between CD47 expression and demographic and clinicopathological feature of CRC patients.

Funding:
This research was self-funded and no external entities were involved.

Author contributions:
Study conception & design: (Fatima O. Abdalkareem and Dr. Ban J. Mohamad), Literature search: (Fatima O. Abdalkareem), Data acquisition: (Fatima O. Abdalkareem), Data analysis & interpretation, Manuscript preparation (Fatima O. Abdalkareem and Dr. Ban J. Mohamad).

Authors' declaration:
Conflicts of Interest: None
We confirm that all the Figures and Tables in the manuscript are mine/ ours. Besides, the authors have signed an ethical consideration’s approval-Ethical Clearance. The project was approved by the local ethical committee in the College of Science, according to the guidelines on biomedical research, The license has the code number CSEC/0922/0109 and dated on September 28, 2022.
References


5. Al-Rubataee SAT, Al-Tae TJK. Detection of BRAFV600E Biomarker in Patients with Colorectal Cancer Using Immunohistochemical Techniques/A ClinicPathological Study. Journal of the Faculty of Medicine. 2022;64(1) https://doi.org/10.32007/jfacmedbagdad.641188.


How to Cite this Article
التعبير النسيجي الكيميائي المناعي لبروتين CD47 في سرطان القولون في المرضى العراقيين

فاطمة عمر عبد الكريم 1، بيان جاسم محمد 1
فرع علوم الحياة، كلية العلم. جامعة بغداد، بغداد العراق

الخلاصة:
خلفية البحث: سرطان الأمعاء هو أحد أكثر الأورام الخبيثة شيوعاً في الجهاز الهضمي ويعتبر السبب الرابع للوفيات بسبب السرطان في العالم. في العراق، يعتبر سرطان القولون والمستقيم أحد الأورام الخبيثة والمبكرة والأكثر شيوعًا في الرجال والنساء. بسبب النمو البطيء، لهذا النوع من السرطان، هناك فرصة لفحص كل من السرطان المبكر والآفات المساعدة. مجموعة التمثيل 47 (CD47) هو أحد أنواع البروتينات الغشائية السكرية ويوجد تقريباً في جميع خلاياجسم الإنسان، والتي تشمل الخلايا المكونة للملاذ وغير المكونة للملاذ. CD47 يحفز نمو سرطان القولون عن طريق تكوين الوعود الدموية والموت المبرمج للخلايا السرطانية.

الأهداف: تقييم التعبير الكيميائي المناعي لبروتين CD47 في عينات مختلفة لسرطان القولون في المرضى العراقيين عن طريق الفحص.

المنهجية: تم جمع 45 عينة من سرطان القولون والمستقيم المنجمة في شعاع الرياض والمحافظات séjour من مستشفى مدينة الطب التعليمية. المختبرات الخاصة في بغداد، العراق. بالإضافة إلى ذلك تم جمع 30 عينة من القولون والمستقيم التي لا تعاني حالة مرضية من قسم الطب الشرعي لأغراض المقارنة في هذه الدراسة. بعد إجراء المواقف الرسمية.

النتائج: أظهرت النتائج وجود تعبير عالي لـ CD47 في سرطان القولون والمستقيم، ولم يظهر أي ارتباط معنوي بين الينات السريرية والمرضية. أيضًا، أظهرت النتائج الصارمة في هذه الدراسة عن تعبير غشائي شبيه لـ CD47 (النتيجة 0)، وتعبير غشائي قوي لـ CD47 (النتيجة 8)، وتعبير غشائي ضعيف لـ CD47 (النتيجة 7). الاستنتاجات: أظهرت الدراسة التقييمية تعبيرًا عالياً لـ CD47 في المرضى الذين يعانون من سرطان القولون والمستقيم، مما يسمح للخلايا السرطانية بالتحكم الإشارات المنطقة لـ CD47-SIRPa.

مفتاح الكلمات: سرطان القولون والمستقيم، مجموعة التمثيل 47، الكيمياء المناعية السرطانية، البروتين المرتبط بالإنترنين.